This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

About Prevnar 13About Prevnar 13Mechanism of ActionSerotype coverageIncidence of IPD and Colonization dataExperienceImmunogenicityDosingDosingDosingEfficacy and Safety ProfileEfficacy and Safety ProfileEfficacy profileSafety profileGuidelinesGuidelinesGuidelinesResourcesResourcesMaterialsVideos
Product MonographImportant Safety Information 

Incidence of IPD

Colonization data

Tab Number 3

Incidence of IPD since the introduction of Prevnar 7The introduction of Prevnar to routine programs in Canada has led to a substantial reduction of IPD due to the serotypes contained in the vaccine1

Reported reduction of incidence of IPD caused by Prevnar (Pneumococcal 7-valent Conjugate Vaccine) serotypes in infants and young children

Adapted from the Prevnar 13 Product Monograph.Prior to the licensure of Prevnar in Canada in 2001, the observed incidence rates of IPD among children <2 years of age and <5 years of age were 58.8-112.2 per 100,000 and 35.0-63.8 per 100,000 per year, respectively. 

Prevnar (Pneumococcal 7-valent Conjugate Vaccine) has been discontinued in Canada.

IPD: invasive pneumococcal disease.References:Prevnar® 13 Product Monograph. Pfizer Canada ULC. 2022.Ricketson LJ et al. Trends in asymptomatic nasopharyngeal colonization with Streptococcus pneumoniae after introduction of the 13-valent pneumococcal conjugate vaccine in Calgary, Canada. Pediatr Infect Dis J. 2014;33:724–30.
Colonization dataFollowing the introduction of Prevnar 13, 
the rates of pneumococcal nasopharyngeal colonization in healthy children declined1,2*†Adapted from the Prevnar 13 Product Monograph and Ricketson LJ et al.RR: relative reduction.Based on surveys conducted by the Calgary Area S. pneumoniae Epidemiology Research (CASPER) team within the Calgary zone of Alberta Health Services.Comparative clinical significance has not been established.Prevnar (Pneumococcal 7-valent Conjugate Vaccine) has been discontinued in Canada.References:Prevnar® 13 Product Monograph. Pfizer Canada ULC. 2022.Ricketson LJ et al. Trends in asymptomatic nasopharyngeal colonization with Streptococcus pneumoniae after introduction of the 13-valent pneumococcal conjugate vaccine in Calgary, Canada. Pediatr Infect Dis J. 2014;33:724–30.
About Prevnar 13
NEXT

Experience

 Visit page Loading
EXPLORE MORE

Efficacy data

 Visit page Loading
PP-PRV-CAN-0016-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN